The way COVID-19 vaccines are distributed globally could profoundly affect future death tolls, according to a Northeastern University report commissioned by the Bill & Melinda Gates Foundation. If high-income countries monopolize early supplies, it could result in twice as many deaths compared to fair sharing.
Over a dozen vaccine candidates are in phase 3 trials, the final stage before potential approval. Early results are promising: Pfizer and BioNTech reported 90% efficacy on November 9, later updated to 95% with new data. Moderna followed with an estimated 94.5% efficacy rate and plans to seek emergency use authorization from the FDA by December 2020.
Russia's Sputnik V vaccine shows 92% efficacy, per Health Minister Mikhail Murashko, and distribution has begun domestically to 10,000 high-risk individuals and healthcare workers.
These breakthroughs have sparked global optimism and massive orders. The European Union secured 200 million doses of Pfizer's candidate, with an option for 100 million more. Over 50 countries expressed interest in Sputnik V, with more than 1.2 billion doses in production.
Prioritizing recipients domestically is critical. France's High Authority for Health recommended focusing on healthcare workers, those over 65, people with chronic conditions, and obese individuals—requiring 46 million doses in total.
Internationally, wealthier nations are preemptively securing limited supplies. The Gates Foundation report modeled two scenarios: one where about 50 high-income countries claim the first two billion doses, and another with equitable distribution based on population.
Equitable distribution could avert 61% of deaths, versus just 33% under the hoarding scenario. "It's a significant gap," says lead author Alessandro Vespignani. "Globally, fairness outperforms self-interest—not just ethically, but in saving lives."
To sidestep uncertain pandemic forecasts, researchers simulated vaccine availability from mid-March 2020, during the first wave. They assumed 65-80% efficacy from a single dose two weeks post-administration, with three billion doses total.
Uncertainties remain, Vespignani notes: future immunity levels, true vaccine performance, and countries' distribution capabilities. "Many variables aren't modeled yet." Still, the findings are stark: "Cooperation halves deaths worldwide." Decisions should draw from multiple models, but collaboration clearly saves lives.
